Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen Wiviott (1) , Itamar Raz , Marc P Bonaca (2) , Ofri Mosenzon , Eri Kato , Avivit Cahn , Michael Silverman , Thomas Zelniker , Julia Kuder (1) , Sabina Murphy (1) , Deepak Bhatt (3) , Lawrence Leiter , Darren Mcguire , John P.H. Wilding , Christian Ruff , Ingrid A.M. Gause-Nilsson , Martin Fredriksson , Peter Johansson (4) , Anna-Maria Langkilde , Marc S Sabatine (2)

1 BWH - Brigham & Women’s Hospital [Boston]
2 HMS - Harvard Medical School [Boston]
3 VA Boston Healthcare System
4 Turbulence Research Laboratory [Goteborg]

Domaines: Sciences du Vivant [q-bio]; Biologie cellulaire; Sciences pharmaceutiques; Alimentation et Nutrition; Biologie animale

Stephen Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri Kato, et al.. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380 (4), pp.347-357. ⟨10.1056/NEJMoa1812389⟩. ⟨hal-02543624⟩